Immunotherapy in Systemic Primary (AL) Amyloidosis Using Amyloid-Reactive Monoclonal Antibodies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 6, 2003, Pages 853-860

  Solomon, Alan ^a,b   Weiss, Deborah T ^a   Wall, Jonathan S ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

Amyloidosis; Light chains; Monoclonal antibodies; Passive immunotherapy

Indexed keywords

4' IODOESORUBICIN; ANTHRACYCLINE DERIVATIVE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 11 1F4; RITUXIMAB; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANIMAL MODEL; CHIMERA; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; TREATMENT OUTCOME;

EID: 0347569588     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322702824     Document Type: Review

References (74)

1. Solomon A, Weiss DT. Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid 1995;2:269.
2. Kyle RA, Gertz M.A. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45.
3. Dhodapkar MV, Merlini G, Solomon A. Biology and therapy of immunoglobulin deposition diseases. Hematol Oncol Clin North Am 1997;11:89.
4. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898.
5. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases. Blood 1986;68:220.
6. Gertz MA, Kyle RA. Amyloidosis: Prognosis and treatment. Semin Arthritis Rheum 1994;24:124.
7. Berg AM, Anderson JJ, Chipkin SR, et al. Autonomic neuropathy in AL (primary) amyloidosis and its effect on survival. Amyloid 1994;1:39.
8. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998;104:232.
9. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276.
10. Hurle MR, Helms LR, Li L, et al. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA 1994;91:5446.
11. Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem 1997;50: 183.
12. Raffen R, Dieckman LJ, Szpunar M, et al. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci 1999;8:509.
13. Stevens FJ, Weiss DT, Solomon A. Structural bases of light chain-related pathology. In: Zanetti M, Capra JD, eds. The Antibodies, vol. 5, Longhome, PA: Harwood Academic Publishers, 1999:175.
14. Stevens FJ. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 2000;7:200.
15. Snow AD, Wight TN. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 1989;10:481.
16. Pepys MB, Booth DR, Hutchinson WL, et al. Amyloid P component: A critical review. Amyloid 1997;4:274.
17. Cohen HJ, Lessin LS, Hallal J, Burkholder P. Resolution of primary amyloidosis during chemotherapy: Studies in a patient with nephrotic syndrome. Ann Intern Med 1975;82:466.
18. Kyle RA, Greipp PR. Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo. Blood 1978;52:818.
19. Gertz MA, Kyle RA. Response of primary hepatic amyloidosis to melphalan and prednisone: A case report and review of the literature. Mayo Clin Proc 1986;61:218.
20. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77:257.
21. Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995;32:60.
22. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290.
23. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202.
24. Dhodapkar MV, Jagannath S, Vesole D, et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 1997;27:351.
25. Gertz MA, Lacy MQ, Lust JA, et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999;17:262.
26. Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001;113:1044.
27. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998;91:3662.
28. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 1998;101:766.
29. Gilmore JD, Apperley JF, Craddock C, et al. High-dose melphalan and stem cell rescue for AL amyloidosis. In: Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis: The Proceedings of the VIIIth International Symposium on Amyloidosis. New York: Parthenon Publishing Group, 1998:102.
30. Moreau P. Autologous stem cell transplantation for AL amyloidosis: A standard therapy? Leukemia 1999;13: 1929.
31. Comenzo RL, Sanchorawala V, Fisher C, et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999;104:553.
32. Patriarca F, Geromin A, Fanin R, et al. Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura. Bone Marrow Transplant 1999;24: 433.
33. Kyle RA. High-dose therapy in multiple myeloma and primary amyloidosis: An overview. Semin Oncol 1999; 26:74.
34. Sezer O, Schmid P, Shweigert M, et al. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 1999;23:967.
35. Sezer O, Eucker J, Schmid P, Possinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 2000;79:1.
36. Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000;26: 963.
37. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: A status report. Bone Marrow Transplant 2000;25:465.
38. Comenzo RL. Hematopoietic cell transplantation for primary systemic amyloidosis: What have we learned? Leuk Lymphoma 2000;37:245.
39. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001;19:3350.
40. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549.
41. van Gameren II, Hazenberg BP, Jager PL, et al. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid: J Protein Folding Disord 2002;9:165.
42. Seldin DC. AL amyloidosis, a curable disease? Amyloid: J Protein Folding Disord 2002;9:203.
43. Schulenburg A, Kalhs P, Oberhuber G, et al. Gastrointestinal perforation early after peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 1998;22:293.
44. Schuh A, Dandridge J, Haydon P, Littlewood TJ. Encephalopathy complicating high-dose melphalan. Bone Marrow Transplant 1999;24:1141.
45. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999;24:853.
46. Akasheh MS, Chang CP, Vesole DH. Acute tumour lysis syndrome: A case in AL amyloidosis. Br J Haematol 1999;107:387.
47. Benekli M, Anderson B, Wentling D, et al. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. Bone Marrow Transplant 2000;25:1299.
48. Kumar S, Dispenzieri A, Lacy MQ, et al. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001;28:381.
49. Gertz MA, Kyle RA. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 1990;150: 629.
50. Richter G. The resorption of amyloid under experimental conditions. Am J Pathol 1954;30:239.
51. Wegelius O. The resolution of amyloid substance. Acta Med Scand 1982;212:273.
52. Hawkins PN, Richardson S, MacSweeney JE, et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide for turnover and regression. QJM 1993;86:365.
53. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: Resorption of AL-type deposits with 4′-iodo-4′ -deoxydoxorubicin. Blood 1995;86:855.
54. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995;92:2959.
55. Merlini G, Anesi E, Garini P, et al. Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin: An update. Blood 1999;93:1112.
56. Gertz MA, Lacy MQ, Dispenzieri A, et al. A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid: J Protein Folding Disord 2002;9:24.
57. Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease. Nat Med 1995;1:143.
58. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995;92:4299.
59. Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000;157:1239.
60. Wilson RW, Ballantyne CM, Smith CW, et al. Gene targeting yields a CD18. J Immunol 1993;151:1571.
61. Solomon A, McLaughlin CL. Bence-Jones proteins and light chains of immunoglobulins. I. Formation and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves. J Biol Chem 1969;244:3393.
62. Wall J, Schell M, Hrncic R, et al. Treatment of amyloidosis using an anti-fibril monoclonal antibody: Preclinical efficacy in a murine model of AA-amyloidosis. In: Bély M, Apáthy A, eds. Amyloid and Amyloidosis. The Proceedings of the IX International Symposium on Amyloidosis. Hungary; 2001:158.
63. Ishihara T. Experimental amyloidosis using silver nitrate-electron microscopic study on the relationship between silver granules, amyloid fibrils and reticuloendothelial system. Acta Pathol Jpn 1973;23:439.
64. Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11. Clin Cancer Res 2003;9:38315.
65. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188.
66. Azeredo da Silveira S, Kikuchi S, Fossati-Jimack L, et al. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med 2002; 195:665.
67. Wall J, Murphy CL, Solomon A. In vitro immunoglobulin light chain fibrilogenesis. Methods Enzymol 1999; 309:204.
68. Solomon B, Koppel R, Hanan E, Katz VT. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 1996;93:452.
69. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109.
70. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916.
71. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003;100:2023.
72. O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 2002;99:1485.
73. Solomon A, Weiss DT, Macy SD, Antonucci RA. Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies. Am J Pathol 1990;137:855.
74. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135.